NASDAQ:EBIO - Eleven Biotherapeutics Stock Price, Price Target & More

Eleven Biotherapeutics trades on the NASDAQ under the ticker symbol "EBIO."

Eleven Biotherapeutics (NASDAQ:EBIO) posted its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.03. View Eleven Biotherapeutics' Earnings History.

2 brokerages have issued 12-month target prices for Eleven Biotherapeutics' stock. Their predictions range from $2.00 to $8.00. On average, they expect Eleven Biotherapeutics' stock price to reach $5.00 in the next twelve months. View Analyst Ratings for Eleven Biotherapeutics.

Eleven Biotherapeutics saw a increase in short interest in May. As of May 15th, there was short interest totalling 6,739,239 shares, an increase of 48.5% from the April 30th total of 4,536,882 shares. Based on an average daily volume of 6,663,859 shares, the short-interest ratio is presently 1.0 days. View Eleven Biotherapeutics' Current Options Chain.

Some companies that are related to Eleven Biotherapeutics include Viking Therapeutics (VKTX), Progenics Pharmaceuticals (PGNX), Akebia Therapeutics (AKBA), Kura Oncology (KURA), Aclaris Therapeutics (ACRS), ChemoCentryx (CCXI), Keryx Biopharmaceuticals (KERX), Beyondspring (BYSI), Five Prime Therapeutics (FPRX), Prothena (PRTA), Insys Therapeutics (INSY), Lannett (LCI), Cara Therapeutics (CARA), Stemline Therapeutics (STML) and TIGENIX/S (TIG).

Press coverage about EBIO stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eleven Biotherapeutics earned a daily sentiment score of 0.09 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.40 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Eleven Biotherapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include SABBY MANAGEMENT, LLC (7.40%), SABBY MANAGEMENT, LLC (7.40%), Highbridge Capital Management LLC (3.33%), Sabby Management LLC (2.57%) and Millennium Management LLC (0.51%). Company insiders that own Eleven Biotherapeutics stock include Abbie Celniker, John J Mccabe, Karen L Tubridy, Ventures Fund 2007 L Flagship and Ventures Fund Iv LP Flagship. View Institutional Ownership Trends for Eleven Biotherapeutics.

EBIO stock was purchased by a variety of institutional investors in the last quarter, including Highbridge Capital Management LLC, Sabby Management LLC and Millennium Management LLC. View Insider Buying and Selling for Eleven Biotherapeutics.

Shares of EBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EBIO stock can currently be purchased for approximately $3.29.

Eleven Biotherapeutics has a market capitalization of $159.20 million and generates $430,000.00 in revenue each year. The biopharmaceutical company earns $-29,020,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. Eleven Biotherapeutics employs 17 workers across the globe.

Eleven Biotherapeutics' mailing address is 215 FIRST STREET SUITE 400, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-9911 or via email at [email protected]